In vivo microdialysis was used to study the effects of systemic, as we
ll as intracerebral administration of morphine and naloxone on dynorph
in B release in neostriatum and substantia nigra of rats. The release
of dopamine (DA), gamma-aminobutyric acid (GABA), glutamate (Glu) and
aspartate (Asp) was also investigated. Systemic injection of morphine
(1 mg/kg s.c.) induced long-lasting increases in extracellular dynorph
in B and GABA levels in the substantia nigra, whereas DA, Glu and Asp
levels, measured in the same region, were not significantly affected.
No effect on striatal neurotransmitter levels was observed following s
ystemic morphine administration. Local perfusion of the substantia nig
ra with morphine (100 mu M) through the microdialysis probe also incre
ased nigral dynorphin B and GABA levels. Perfusion of the neostriatum
with morphine (100 mu M) significantly increased GABA and dynorphin B
levels in the ipsilateral substantia nigra, but no effect was observed
locally. Naloxone blocked the effect of systemic morphine administrat
ion on nigral dynorphin B and GABA release, already at a dose of 0.2 m
g/kg s.c. Naloxone alone, given either systemically (0.2-4 mg/kg s.c.)
or intracerebrally (1-100 mu M), did not affect dynorphin B or amino
acid levels, either in neostriatum or in substantia nigra. However, na
loxone produced a concentration-dependent increase in DA levels. The p
resent results indicate that systemic morphine administration stimulat
es the release of dynorphin B in the substantia nigra, probably by act
ivating the mu-subtype of opioid receptor, since the effect of morphin
e on nigral dynorphin B and GABA was antagonized by a low dose of nalo
xone. The increase in extracellular DA levels produced by high concent
rations of naloxone, both in neostriatum and substantia nigra, indicat
es a disinhibitory effect of this drug on DA release, probably via a n
on-mu subtype of opioid receptors located on nigro-striatal DA neurone
s.